[Skip to Content]
Sign In
Individual Sign In
Create an Account
Institutional Sign In
OpenAthens Shibboleth
Purchase Options:
[Skip to Content Landing]
Article
November 16, 1984

Reporting Results From Chemotherapy Trials: Does Response Make a Difference in Patient Survival?

Author Affiliations

From the Division of General Internal Medicine and Health Services Research, Department of Medicine, UCLA School of Medicine, Los Angeles.

JAMA. 1984;252(19):2722-2725. doi:10.1001/jama.1984.03350190024013
Abstract

Patients with many common tumors are treated with chemotherapy despite limited evidence of treatment effectiveness. To determine if chemotherapy trials reporting effectiveness actually demonstrated increased survival in treated patients, we reviewed trials published over a two-year period involving four common solid tumors. Of 80 studies, 95% reported response to chemotherapy as an end point. Of 38 studies demonstrating 15% or greater objective response, 76% reported significantly greater survival of responders than of nonresponders. Of 21 studies containing statements supporting treatment effectiveness, 95% based this claim at least in part on the superior survival of responders compared with nonresponders. Because responders may have lived longer without treatment, such comparisons are not valid and may lead to overly optimistic views of chemotherapy effectiveness. Journal editors should be wary of allowing survival comparisons between responders and nonresponders in published reports.

(JAMA 1984;252:2722-2725)

References
1.
References 3, 46, 50-57, 60-63, 68-70, 73-80.
2.
Miller AB, Hoogstraten B, Staquet M, et al:  Reporting results of cancer treatment .  Cancer 1981;47:207-214.Crossref
3.
Brown BW:  Statistical considerations in clinical trials , in Carter SK, Glatstein E, Livingston RB (eds):  Principles of Cancer Treatment . New York, McGraw-Hill Book Co, 1982, pp 46-52.
4.
Payne JE, Pheils MT, Chapuis PH, et al:  The effect of fluorouracil on survival in metastatic colorectal cancer: Fluorouracil response improves survival .  Aust NZ J Surg 1981;51:12-15.Crossref
5.
Silverberg E:  Cancer statistics 1983 .  CA 1983;33:17.
6.
Frey C, Twomey P, Keehn R, et al:  Randomized study of 5-FU and CCNU in pancreatic cancer: Report of the Veterans Administration surgical adjuvant cancer chemotherapy study group .  Cancer 1981;47:27-31.Crossref
7.
Lawton JO, Giles GR, Hall R, et al:  Chemotherapy following palliative resection of gastric cancer .  Br J Surg 1981;68:397-399.Crossref
8.
Mallinson CN, Rake MO, Cocking JB, et al:  Chemotherapy in pancreatic cancer: Results of a controlled, prospective, randomised, multicentre trial .  Br Med J 1980;281:1589-1591.Crossref
9.
Britell JC, Moertel LG, Kvois LK, et al:  Phase II trial of IV 6-thioguanine in advanced colorectal carcinoma .  Cancer Treat Rep 1981; 65:909-910.
10.
Carroll DS, Gralla RJ, Kemeny NE:  Phase II evaluation of N-phosphonacetyl-L-aspartic acid (PALA) in patients with advanced colorectal carcinoma .  Cancer Treat Rep 1980;64:349-351.
11.
Carroll DS, Kemeny N, Lynch G, et al:  Phase II evaluation of 4′-(9-acridinylamino)-methanesulfon-m-anisidide (AMSA) in patients with advanced colorectal carcinoma .  Cancer Treat Rep 1980;64:1149-1150.
12.
Casper ES, Gralla RJ, Kelsen DP, et al:  Phase II evaluation of 4′-(9-acridinylamino)-methanesulfon-m-anisidide (AMSA) in patients with non-small cell lung cancer .  Cancer Treat Rep 1980;64:345-347.
13.
Casper ES, Gralla RJ, Kelsen DP, et al:  Phase II evaluation of N-(phosphonacetyl)-L-aspartic acid (PALA) in patients with non-small cell carcinoma of the lung .  Cancer Treat Rep 1980;64:705-707.
14.
Ferraro JA, Horton J, Weissman C, et al:  Treatment of advanced colorectal carcinoma with AMSA .  Cancer Treat Rep 1981;65:345-347.
15.
Hafstrom L, Ihse I, Jonsson P, et al:  Intraarterial 5-FU infusion with or without oral testolactone treatment in irresectable pancreatic cancer .  Acta Chir Scand 1980;146:445-448.
16.
Lessner HE, Valenstein S, Kaplan R, et al:  Phase II study of L-asparaginase in the treatment of pancreatic carcinoma .  Cancer Treat Rep 1980;64:1359-1361.
17.
Lynch GR, Gralla RJ, Kelsen DP, et al:  Phase II evaluation of metoprine in patients with non-small-cell lung carcinoma .  Cancer Clin Trials 1981;4:273-276.
18.
Lynch G, Currie V, Kemeny N:  Phase II evaluation of metoprine with leucovorin rescue in patients with advanced colorectal carcinoma .  Cancer Clin Trials 1981;4:281-283.
19.
Nichols WC, Moertel CG, Rubin J, et al:  Phase II trial of indicine N-oxide (NDI) in patients with advanced colorectal carcinoma .  Cancer Treat Rep 1981;65:337-339.
20.
Van Echo DA, Diggs CH, Scoltock M, et al:  Phase II evaluation of N-(phosphonacetyl)-L-aspartic acid (PALA) in metastatic adenocarcinoma of the colon or rectum .  Cancer Treat Rep 1980;64:339-342.
21.
Bleiberg H, Rozencweig M, Michels J, et al:  Phase II trial with chlorozotocin in advanced colorectal cancer .  Eur J Cancer Clin Oncol 1981;17:863-866.Crossref
22.
Chapman R, Kelsen D, Gralla R, et al:  Phase II trial of methylglyoxal-bis-(guanylhydrazone) in non-small-cell lung cancer .  Cancer Clin Trials 1981;4:389-391.
23.
Chlebowski RT, Silverberg I, Pajak T, et al:  Treatment of advanced colon cancer with 5-fluorouracil (NSC19893) versus cyclophosphamide (NSC26271) plus 5-fluorouracil: Prognostic aspects of the differential white blood cell count .  Cancer 1980;45:2240-2244.Crossref
24.
Creech RH, Mehta CR, Cohen M, et al:  Results of a phase II protocol for evaluation of new chemotherapeutic regimens in patients with inoperable non-small cell lung carcinoma (EST-2575, generation I) .  Cancer Treat Rep 1981; 65:431-438.
25.
Davis S, Rambotti P, Park YK:  Combination cyclophosphamide, doxorubicin, and cisplatin (CAP) chemotherapy for extensive non-small cell carcinomas of the lung .  Cancer Treat Rep 1981;65:955-958.
26.
Davis S, Pandya MR, Rambotti P:  Single-agent and combination chemotherapy for extensive non-small cell carcinomas of the lung .  Cancer Treat Rep 1980;64:4-5.
27.
Epenetos AA, Amos C, Collis C, et al:  Comparison of two combination chemotherapy regimens in advanced colorectal cancer .  Br Med J 1980;281:587-588.Crossref
28.
Ettinger DS, Stanley KE, Nystrom JS:  Phase II study of high-dose methotrexate in the treatment of patients with non-small cell carcinoma of the lung: An Eastern Cooperative Oncology Group study .  Cancer Treat Rep 1980; 64:1017-1021.
29.
Falkson G, Falkson HC, duPlessia HE, et al:  Anhydro-ara-5-fluorocytidine (AAFC) in gastrointestinal cancer .  Cancer Clin Trials 1980; 3:341-343.
30.
Gracia JM, Izarzugaza I, Valle M, et al:  Chemotherapy studies in non-small cell bronchogenic carcinoma .  Int J Radiat Oncol Biol Phys 1981;6:1067-1069.Crossref
31.
Haas CD, Baker L, Thigpen T:  Phase II evaluation of dianhydrogalactitol in lung cancer: A Southwest Oncology Group study .  Cancer Treat Rep 1981;65:115-117.
32.
Homma H, Niitani H:  A preliminary report on the treatment of lung cancer with pepleomycin .  Cancer Treat Rev 1980;7:183-189.Crossref
33.
Horton J, Gelber RD, Engstrom P, et al:  Trials of single-agent and combination chemotherapy for advanced cancer of the pancreas .  Cancer Treat Rep 1981;65:65-68.
34.
Lawton JO, Giles GR, Hall J, et al:  Phase II study of chlorozotocin in the treatment of advanced colorectal cancer .  Cancer Treat Rep 1981;65:13-15.
35.
Livingston RB, Mira J, O'Bryan RM:  Four-drug combination chemotherapy in extensive non-small cell lung cancer: A Southwest Oncology Group pilot study .  Cancer Treat Rep 1981; 65:143-144.
36.
Lynch G, Kemeny N, Currie V:  Phase II evaluation of metroprine in patients with advanced colorectal carcinoma .  Cancer Treat Rep 1981;65:127-128.
37.
Nair KG, Moayeri H, Mittelman A:  A phase II study of fluorodopan in the treatment of advanced colorectal cancer .  Cancer Treat Rep 1980;64:697-699.
38.
Nichols WC, Eagan RT, Frytak S, et al:  Phase II evaluation of AMSA in patients with metastic lung cancer .  Cancer Treat Rep 1980; 64:1383-1385.
39.
O'Connell MJ, Moertel CG, Rubin J, et al:  Lack of clinical therapeutic synergism between cyclophosphamide, Adriamycin, and cis-dichlorodiammineplatinum(II) in metastic human colorectal carcinoma .  Cancer Treat Rep 1980; 64:311-313.
40.
Pannuti F, Lelli G, Casadio M, et al:  High-dose cyclophosphamide versus cyclophosphamide, methotrexate, 5-FU, and hydroxyurea (CMFH) in the treatment of stage III non-small cell bronchogenic carcinoma: A randomized trial .  Cancer Treat Rep 1980;64:1131-1134.
41.
Paul AR, Catalano RB, Engstrom PF:  Phase III study of ICRF-159 versus 5-FU in the treatment of advanced metastatic colorectal carcinoma .  Cancer Treat Rep 1980;64:1047-1049.
42.
Rubin J, Purvis J, Britell JC, et al:  Phase II study of PALA in advanced large bowel carcinoma .  Cancer Treat Rep 1981;65:335-336.
43.
Samson MK, Fraile RJ, Baker LH, et al:  Phase II study of AMSA in lung cancer .  Cancer Treat Rep 1981;65:655-658.
44.
Vogl SE, Lanham R, Kaplan BH:  Combination chemotherapy of advanced colorectal cancer with triazinate and ICRDF-159 after failure of 5-fluorouracil .  Oncology 1980;37:314-315.Crossref
45.
Vogl SE, Qazi R, Berenzweig M:  Combination chemotherapy for advanced colorectal cancer with triazinate, ICRF-159, 5-FU, and methyl-CCNU .  Cancer Treat Rep 1980;64:1143-1145.
46.
White DR, Richard F, Muss HB, et al:  Therapy of advanced colorectal carcinoma with 5-fluorouracil and cyclophosphamide in combination with either CCNU or methotrexate .  Cancer 1980;45:662-665.Crossref
47.
Eagan RT, Fleming TR, Frytak S, et al:  A role of cis-dichlorodiammineplatinum (II) in squamous cell lung cancer .  Cancer Treat Rep 1980;64:87-91.
48.
Patt YZ, Mavligit GM, Chuang VP, et al:  Percutaneous hepatic arterial infusion (HAI) of mitomycin C and floxuridine (FUDR): An effective treatment for metastatic colorectal carcinoma in the liver .  Cancer 1980;46:261-265.Crossref
49.
Queiber W, Schnitzler G, Schaefer J, et al:  Comparison of ftorafur with 5-fluorouracil in combination chemotherapy of advanced gastrointestinal carcinoma .  Recent Results Cancer Res 1981;79:82-92.
50.
Lavin P, Mittelman A, Douglas H, et al:  Survival and response to chemotherapy for advanced colorectal adenocarcinoma: An Eastern Cooperative Oncology Group report .  Cancer 1980;46:1536-1543.Crossref
51.
Eagan RT, Frytak S, Nichols WC, et al:  Evaluation of VP-16-213, cyclophosphamide, doxorubicin, and cisplatin (V-CAP) in advanced large cell lung cancer .  Cancer Treat Rep 1981; 65:715-717.
52.
Bukowski RM, Abderhalden RT, Hewlett JS, et al:  Phase II trial of streptozotocin, mitomycin C, and 5-fluorouracil in adenocarcinoma of the pancreas .  Cancer Clin Trials 1980;3:321-324.
53.
Vaughn CB, Brady P, Chinn BJ, et al:  Combination chemotherapy in advanced gastrointestinal malignancy .  Oncology 1980;37:57-61.Crossref
54.
Kemeny N, Yagoda A, Braun D, et al:  Therapy for metastatic colorectal carcinoma with a combination of methyl-CCNU, 5-fluorouracil, vincristine and streptozotocin (MOF-strep) .  Cancer 1980;45:876-881.Crossref
55.
Presant CA, Hillinger S, Klahr C:  Phase II study of 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU,NSC #409962) with amphotericin B in bronchogenic carcinoma .  Cancer 1980;45:6-10.Crossref
56.
Gagliano RG, Panettiere FJ, Haas CD, et al:  Evaluation of beta-2′-deoxythioguanosine combined with methyl-CCNU or mitomycin in advanced colorectal cancer: A Southwest Oncology Group study .  Cancer Clin Trials 1981;4:401-405.
57.
Milstein D, Robinson E:  Four-drug combination chemotherapy in advanced lung cancer: Methotrexate, doxorubicin, cyclophosphamide and CCNU .  Cancer 1981;48:2358-2363.Crossref
58.
Jordan WM, Valdivieso M, Frankmann C, et al:  Treatment of advanced adenocarcinoma of the lung with ftorafur, doxorubicin, cyclophosphamide, and cisplatin (FACP) and intensive IV hyperalimentation .  Cancer Treat Rep 1981; 65:197-205.
59.
Ruckdeschel JC, Mehta CR, Salazar OM, et al:  Chemotherapy for inoperable, non-small cell bronchogenic carcinoma: EST 2575, generation II .  Cancer Treat Rep 1981;65:965-972.
60.
Vincent RG, Mehta CR, Tucker RD, et al:  Chemotherapy of extensive large cell and adenocarcinoma of the lung: A randomized trial in 210 patients .  Cancer 1980;46:256-260.Crossref
61.
Aroney RS, Dalley DN, Chan WK, et al:  Methyl-CCNU, 6-thioguanine and 5-fluorouracil in advanced colorectal cancer .  Med Pediatr Oncol 1981;9:181-186.Crossref
62.
Cambareri RJ, Smith FP, MacDonald JS, et al:  CAMP (cyclophosphamide, doxorubicin, methotrexate, and procarbazine) for epidermoid and large cell anaplastic carcinoma of the lung .  Cancer Treat Rep 1981;65:317-320.
63.
Drapkin R, Bjornsson S, Naeher C, et al:  Docorubicin, cisplatin, and Corynebacterium parvum in non-small cell bronchogenic carcinoma .  Cancer Treat Rep 1980;64:1367-1369.
64.
Eagan RT, Frytak S, Nichols WC, et al:  Phase II study of the combination of dianhydrogalactitol, doxorubicin, and cisplatin (DAP) in patients with advanced squamous cell lung cancer .  Cancer Treat Rep 1981;65:517-519.
65.
Shaw MT, Bonnet JC, Wilson H, et al:  Baker's antifol in combination with 5-fluorouracil and methyl-CCNU in the treatment of metastatic colorectal cancer: A Southwest Oncology Group study (protocol 7764) .  Cancer Treat Rep 1980;64:247-250.
66.
Vogl SE, Wollner D, Kaplan BH, et al:  Combination chemotherapy for non-small cell bronchogenic carcinoma with bleomycin, doxorubicin, methotrexate, and cis-dichlorodiammineplatinum (II) (BAMP) .  Cancer Treat Rep 1980;64:717-719.
67.
Conroy JF, Roda PI, Brodsky I, et al:  Efficacy of dacarbazine imidazole carboxamide and mitomycin C combination therapy in patients with adenocarcinoma of the colon refractory to 5-fluorouracil therapy .  Recent Results Cancer Res 1981;79:93-100.
68.
Franks CR:  Adriamycin and methotrexate in metastatic gastric cancer: A pilot study .  Clin Oncol 1980;6:309-315.
69.
Eagan RT, Frytak S, Ingle JN, et al:  Phase II evaluation of the combination of triazinate, cyclophosphamide, doxorubicin, and cis-diamminedichloroplatinum (II) in patients with advanced adenocarcinoma of the lung .  Cancer Treat Rep 1980;64:925-928.
70.
Gralla FJ, Casper ES, Kelsen DP, et al:  Cisplatin and vindesine combination chemotherapy for advanced carcinoma of the lung: A randomized trial investigating two dosage schedules .  Ann Intern Med 1981;95:414-420.Crossref
71.
Jamieson GG, Gill PG:  A prospective trial of 5-FU and BCNU in the treatment of advanced gastric cancer .  Aust NZ J Surg 1981;51:16-19.Crossref
72.
Schein PS, Macdonald JS, Wooley PV, et al:  The FAM regimen for gastric cancer: A progress report .  Recent Results Cancer Res 1981; 76:241-243.
73.
Takita H, Edgerton F, Marabell A, et al:  Platinum-based combination chemotherapy in non-small cell lung carcinoma .  Cancer 1981; 48:1528-1530.Crossref
74.
Eagan RT, Fleming TR, Lee RE, et al:  Chemotherapy response as a prognosticator for survival in patients with limited squamous cell lung cancer treated with combined chemotherapy and radiotherapy .  Int J Radiat Oncol Biol Phys 1980;6:879-883.Crossref
75.
Rosi DR, Nogeire C, Brown B, et al:  5-Fluorouracil, Adriamycin, and mitomycin-C (Hi-FAM) chemotherapy for adenocarcinoma of the lung .  Cancer 1981;48:21-25.Crossref
76.
Vaughn CB, Chapman JL, Garland M, et al:  The efficacy of 5-fluorouracil, mitomycin C, and methyl CCNU in advanced gastrointestinal malignancy .  Oncology 1981;38:129-133.Crossref
77.
Miller TP, McMahon LJ, Livingston RB:  Extensive adenocarcinoma and large cell undifferentiated carcinoma of the lung treated with 5-FU, vincristine, and mitomycin C (FOMi) .  Cancer Treat Rep 1980;64:1241-1245.
78.
Myers JW, Knight WA, Livingston RB, et al:  Phase I-II trial of methyl-GAG in advanced colon cancer: A Southwest Oncology Group pilot study .  Cancer Clin Trials 1981;4:277-279.
79.
Robert F, Omura G, Bartolucci AA:  Combination chemotherapy with cyclophosphamide, Adriamycin, intermediate dose methotrexate, and folinic acid rescue (CAMF) in advanced lung cancer .  Cancer 1980;45:1-5.Crossref
80.
Evans WK, Feld R, DeBoer G, et al:  Cyclophosphamide, doxorubicin, and cisplatin in the treatment of non-small cell bronchogenic carcinoma .  Cancer Treat Rep 1981;65:947-953.
81.
Smith FP, Hoth DF, Levin B, et al:  5-Fluorouracil, Adriamycin, and mitomycin-C (FAM) chemotherapy for advanced adenocarcinoma of the pancreas .  Cancer 1980;46:2014-2018.Crossref
82.
Ruckdeschel JC, Mehta CR, Salazar OM, et al:  Chemotherapy for metastatic non-small cell bronchogenic carcinoma: EST 2575, generation III, HAM versus CAMP .  Cancer Treat Rep 1981;65:959-963.
83.
MacDonald JS, Schein PS, Woolley PV, et al:  5-Fluorouracil, doxorubicin, and mitomycin (FAM) combination chemotherapy for advanced gastric cancer .  Ann Intern Med 1980;93:533-536.Crossref
84.
Friedman M, Ogawa M, Hannigan J, et al:  Preliminary results of a United States-Japan cooperative trial in patients with disseminated gastric cancer .  Recent Results Cancer Res 1981; 76:249-256.
×